Laboratorio Nacional Biobanco, Mexico

Registration Status: Pending

Objective: A leading institution in patient care and clinical research needs to obtain the greatest profit from the clinical samples of the patients it serves. Thus, it should shelter any surgical samples and, whenever possible, other body fluids (blood, urine, cerebrospinal fluid, liquid-based cytology, etc.) from deserving cases. However, this does not always occur. When it does occur, it is not always performed in the right way, and when it is, the samples are usually not used beyond immediate traditional analyses and therefore they are not preserved long enough to serve as a reference for future studies. The integration of a BioSpecimens Research Program into the clinical practice of such leading institutions, allows more and better discoveries by graduate students, scholars and researchers, that can be of world impact. Similarly, there is an added value for pharmaceutical and biotech companies seeking to innovate diagnoses and treatments. The specific aims being pursued for the project are: 1. Obtain the approval of the project by the Institutional Ethics Committee on Research. 2. Negotiate and sign inter-institutional collaboration agreements with the international advisers.3. Adaptations and equipping physical spaces at headquarters to build the facilities. 4. Equipping and conditioning space at each headquarter (UANL and INCMNSZ). 4. Moving the biospecimens from the Pilot Biobank to the new facilities at each headquarter. 5. Functional testing of each headquartersâ€™ infrastructure. 6. Standardization of procedures and their accreditation. 7. Quality management system, including marketing and outreach programs. 8. Exchange of experiences with international leading biobanks. 9. Audits by the Biobank Network of Valencia, Spain. 10. Formation of highly qualified human resources through servicing thesis and research projects. 11. Negotiate biobanking services pharmaceutical companies for their sponsored clinical protocols. 12. Fostering a national network of biobanks

Registered Biobank Name	Laboratorio Nacional Biobanco
Biobank Leader	Hugo Alberto Barrera SaldaÃ±a
Country	Mexico
Email for biobank inquiries	habarrera@gmail.com
Principal Investigator	Hugo Alberto Barrera SaldaÃ±a
Website	http://www.medicina.uanl.mx/biobanco/
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).